IL5 and acute myeloid leukemia: One such study in AML revealed that mesenchymal stem cell-derived prostaglandin D2 (PGD2) is capable of activating ILC2s via the CRTH2 receptor to secrete IL-5, resulting in expansion of Treg populations and promoting HSPC proliferation [33].